The Genomic Landscape of the Ewing Sarcoma Family of Tumors Reveals Recurrent STAG2 Mutation

PLoS Genetics

Volumn 10, Issue 7, 2014, Pages

  Brohl, Andrew S ^a,b   Solomon, David A ^c   Chang, Wendy ^a   Wang, Jianjun ^a   Song, Young ^a   Sindiri, Sivasish ^a   Patidar, Rajesh ^a   Hurd, Laura ^a   Chen, Li ^a   Shern, Jack F ^a   Liao, Hongling ^a   Wen, Xinyu ^a   Gerard, Julia ^d   Kim, Jung Sik ^d   Lopez Guerrero, Jose Antonio ^e   Machado, Isidro ^e   Wai, Daniel H ^f   Picci, Piero ^g   Triche, Timothy ^f   Horvai, Andrew E ^c   Miettinen, Markku ^a   Wei, Jun S ^a   Catchpool, Daniel ^d   Llombart Bosch, Antonio ^e   Waldman, Todd ^h   Khan, Javed ^a   more..

^a NATIONAL CANCER INSTITUTE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^e UNIVERSITY OF VALENCIA   (Spain)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^g RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^h GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA2 PROTEIN; COHESIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; PROTEIN P53; PROTEIN STAG2; TRANSCRIPTOME; UNCLASSIFIED DRUG; CELL NUCLEUS ANTIGEN; STAG2 PROTEIN, HUMAN; TUMOR PROTEIN;

ADVANCED CANCER; ARTICLE; BRCA2 GENE; CANCER GENETICS; CANCER PATIENT; CANCER SURVIVAL; CDKN2A GENE; CIC FOXO4 GENE; COHORT ANALYSIS; CONTROLLED STUDY; DNA POLYMORPHISM; EWING SARCOMA; EWING SARCOMA FAMILY OF TUMOR; FUS NCATC2 GENE; FUSION GENE; GENE DELETION; GENE EXPRESSION PROFILING; GENE SEQUENCE; GENE TARGETING; GENOME ANALYSIS; GENOMICS; HISTOPATHOLOGY; HOMOZYGOTE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MOLECULAR GENETICS; MUTATIONAL ANALYSIS; ONCOGENE; OVERALL SURVIVAL; POPULATION GENETICS; PREVALENCE; RNA SEQUENCE; SOMATIC MUTATION; STAG2 GENE; TISSUE MICROARRAY; TP53 GENE; TUMOR CELL; ADOLESCENT; ADULT; CHILD; DISEASE FREE SURVIVAL; FEMALE; GENETICS; HIGH THROUGHPUT SEQUENCING; HUMAN GENOME; INFANT; MALE; MUTATION; PATHOLOGY; PRESCHOOL CHILD; SARCOMA, EWING; TUMOR CELL LINE;

ADOLESCENT; ADULT; ANTIGENS, NUCLEAR; CELL LINE, TUMOR; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; GENE DELETION; GENOME, HUMAN; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; INFANT; MALE; MUTATION; NEOPLASM PROTEINS; SARCOMA, EWING;

EID: 84905457348     PISSN: 15537390     EISSN: 15537404     Source Type: Journal    
DOI: 10.1371/journal.pgen.1004475     Document Type: Article

References (62)

1. Howlader N, Noone A, Krapcho M, Garshell J, Neyman N, et al. (2013) SEER Cancer Statistics Review (1975-2010). Available: http://seer.cancer.gov/csr/1975_2010/. Accessed 11 June 2014.
2. Barker LM, Pendergrass TW, Sanders JE, Hawkins DS, (2005) Survival after recurrence of Ewing's sarcoma family of tumors. J Clin Oncol 23: 4354-4362.
3. Esiashvili N, Goodman M, Marcus RB Jr, (2008) Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades: Surveillance Epidemiology and End Results data. J Pediatr Hematol Oncol 30: 425-430.
4. Delattre O, Zucman J, Melot T, Garau XS, Zucker JM, et al. (1994) The Ewing family of tumors-a subgroup of small-round-cell tumors defined by specific chimeric transcripts. N Engl J Med 331: 294-299.
5. Turc-Carel C, Aurias A, Mugneret F, Lizard S, Sidaner I, et al. (1988) Chromosomes in Ewing's sarcoma. I. An evaluation of 85 cases of remarkable consistency of t(11;22)(q24;q12). Cancer Genet Cytogenet 32: 229-238.
6. Sankar S, Lessnick SL, (2011) Promiscuous partnerships in Ewing's sarcoma. Cancer Genet 204: 351-365.
7. Armengol G, Tarkkanen M, Virolainen M, Forus A, Valle J, et al. (1997) Recurrent gains of 1q, 8 and 12 in the Ewing family of tumours by comparative genomic hybridization. Br J Cancer 75: 1403-1409.
8. Savola S, Klami A, Tripathi A, Niini T, Serra M, et al. (2009) Combined use of expression and CGH arrays pinpoints novel candidate genes in Ewing sarcoma family of tumors. BMC Cancer 9: 17.
9. Hattinger CM, Rumpler S, Strehl S, Ambros IM, Zoubek A, et al. (1999) Prognostic impact of deletions at 1p36 and numerical aberrations in Ewing tumors. Genes Chromosomes Cancer 24: 243-254.
10. Hamelin R, Zucman J, Melot T, Delattre O, Thomas G, (1994) p53 mutations in human tumors with chimeric EWS/FLI-1 genes. Int J Cancer 57: 336-340.
11. Kovar H, Auinger A, Jug G, Aryee D, Zoubek A, et al. (1993) Narrow spectrum of infrequent p53 mutations and absence of MDM2 amplification in Ewing tumours. Oncogene 8: 2683-2690.
12. Kovar H, Jug G, Aryee DN, Zoubek A, Ambros P, et al. (1997) Among genes involved in the RB dependent cell cycle regulatory cascade, the p16 tumor suppressor gene is frequently lost in the Ewing family of tumors. Oncogene 15: 2225-2232.
13. Brownhill SC, Taylor C, Burchill SA, (2007) Chromosome 9p21 gene copy number and prognostic significance of p16 in ESFT. Br J Cancer 96: 1914-1923.
14. Huang HY, Illei PB, Zhao Z, Mazumdar M, Huvos AG, et al. (2005) Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse. J Clin Oncol 23: 548-558.
15. Lopez-Guerrero JA, Pellin A, Noguera R, Carda C, Llombart-Bosch A, (2001) Molecular analysis of the 9p21 locus and p53 genes in Ewing family tumors. Lab Invest 81: 803-814.
16. Wei G, Antonescu CR, de Alava E, Leung D, Huvos AG, et al. (2000) Prognostic impact of INK4A deletion in Ewing sarcoma. Cancer 89: 793-799.
17. Tsuchiya T, Sekine K, Hinohara S, Namiki T, Nobori T, et al. (2000) Analysis of the p16INK4, p14ARF, p15, TP53, and MDM2 genes and their prognostic implications in osteosarcoma and Ewing sarcoma. Cancer Genet Cytogenet 120: 91-98.
18. Park YK, Chi SG, Kim YW, Park HR, Unni KK, (2001) P53 mutations in Ewing's sarcoma. Oncol Rep 8: 533-537.
19. Komuro H, Hayashi Y, Kawamura M, Hayashi K, Kaneko Y, et al. (1993) Mutations of the p53 gene are involved in Ewing's sarcomas but not in neuroblastomas. Cancer Res 53: 5284-5288.
20. Kan Z, Jaiswal BS, Stinson J, Janakiraman V, Bhatt D, et al. (2010) Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 466: 869-873.
21. Molenaar JJ, Koster J, Zwijnenburg DA, van Sluis P, Valentijn LJ, et al. (2012) Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature 483: 589-593.
22. Shern JF, Chen L, Chmielecki J, Wei JS, Patidar R, et al. (2014) Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. Cancer Discov 4: 216-231.
23. Knezevich SR, McFadden DE, Tao W, Lim JF, Sorensen PH, (1998) A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma. Nat Genet 18: 184-187.
24. Rubin BP, Chen CJ, Morgan TW, Xiao S, Grier HE, et al. (1998) Congenital mesoblastic nephroma t(12;15) is associated with ETV6-NTRK3 gene fusion: cytogenetic and molecular relationship to congenital (infantile) fibrosarcoma. Am J Pathol 153: 1451-1458.
25. Tognon C, Knezevich SR, Huntsman D, Roskelley CD, Melnyk N, et al. (2002) Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell 2: 367-376.
26. Skalova A, Vanecek T, Sima R, Laco J, Weinreb I, et al. (2010) Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity. Am J Surg Pathol 34: 599-608.
27. Leeman-Neill RJ, Kelly LM, Liu P, Brenner AV, Little MP, et al. (2013) ETV6-NTRK3 is a common chromosomal rearrangement in radiation-associated thyroid cancer. Cancer 120: 799-807.
28. Chen QR, Vansant G, Oades K, Pickering M, Wei JS, et al. (2007) Diagnosis of the small round blue cell tumors using multiplex polymerase chain reaction. J Mol Diagn 9: 80-88.
29. Solomon DA, Kim T, Diaz-Martinez LA, Fair J, Elkahloun AG, et al. (2011) Mutational inactivation of STAG2 causes aneuploidy in human cancer. Science 333: 1039-1043.
30. Lopez-Guerrero JA, Machado I, Scotlandi K, Noguera R, Pellin A, et al. (2011) Clinicopathological significance of cell cycle regulation markers in a large series of genetically confirmed Ewing's sarcoma family of tumors. Int J Cancer 128: 1139-1150.
31. Kato M, Yano K, Matsuo F, Saito H, Katagiri T, et al. (2000) Identification of Rad51 alteration in patients with bilateral breast cancer. J Hum Genet 45: 133-137.
32. Zhang J, Benavente CA, McEvoy J, Flores-Otero J, Ding L, et al. (2012) A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature 481: 329-334.
33. Lee RS, Stewart C, Carter SL, Ambrogio L, Cibulskis K, et al. (2012) A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers. J Clin Invest 122: 2983-2988.
34. Hasselblatt M, Isken S, Linge A, Eikmeier K, Jeibmann A, et al. (2013) High-resolution genomic analysis suggests the absence of recurrent genomic alterations other than SMARCB1 aberrations in atypical teratoid/rhabdoid tumors. Genes Chromosomes Cancer 52: 185-190.
35. Chen X, Stewart E, Shelat AA, Qu C, Bahrami A, et al. (2013) Targeting oxidative stress in embryonal rhabdomyosarcoma. Cancer Cell 24: 710-724.
36. Szuhai K, Ijszenga M, de Jong D, Karseladze A, Tanke HJ, et al. (2009) The NFATc2 gene is involved in a novel cloned translocation in a Ewing sarcoma variant that couples its function in immunology to oncology. Clin Cancer Res 15: 2259-2268.
37. Italiano A, Sung YS, Zhang L, Singer S, Maki RG, et al. (2012) High prevalence of CIC fusion with double-homeobox (DUX4) transcription factors in EWSR1-negative undifferentiated small blue round cell sarcomas. Genes Chromosomes Cancer 51: 207-218.
38. Borkhardt A, Repp R, Haas OA, Leis T, Harbott J, et al. (1997) Cloning and characterization of AFX, the gene that fuses to MLL in acute leukemias with a t(X;11)(q13;q23). Oncogene 14: 195-202.
39. Barr FG, Qualman SJ, Macris MH, Melnyk N, Lawlor ER, et al. (2002) Genetic heterogeneity in the alveolar rhabdomyosarcoma subset without typical gene fusions. Cancer Res 62: 4704-4710.
40. Walter MJ, Shen D, Shao J, Ding L, White BS, et al. (2013) Clonal diversity of recurrently mutated genes in myelodysplastic syndromes. Leukemia 27: 1275-1282.
41. Solomon DA, Kim JS, Bondaruk J, Shariat SF, Wang ZF, et al. (2013) Frequent truncating mutations of STAG2 in bladder cancer. Nat Genet 45: 1428-1430.
42. Kon A, Shih LY, Minamino M, Sanada M, Shiraishi Y, et al. (2013) Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms. Nat Genet 45: 1232-1237.
43. Balbas-Martinez C, Sagrera A, Carrillo-de-Santa-Pau E, Earl J, Marquez M, et al. (2013) Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy. Nat Genet 45: 1464-1469.
44. Guo G, Sun X, Chen C, Wu S, Huang P, et al. (2013) Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nat Genet 45: 1459-1463.
45. Mazoyer S, Dunning AM, Serova O, Dearden J, Puget N, et al. (1996) A polymorphic stop codon in BRCA2. Nat Genet 14: 253-254.
46. Plon SE, Eccles DM, Easton D, Foulkes WD, Genuardi M, et al. (2008) Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat 29: 1282-1291.
47. Rudd MF, Webb EL, Matakidou A, Sellick GS, Williams RD, et al. (2006) Variants in the GH-IGF axis confer susceptibility to lung cancer. Genome Res 16: 693-701.
48. Martin ST, Matsubayashi H, Rogers CD, Philips J, Couch FJ, et al. (2005) Increased prevalence of the BRCA2 polymorphic stop codon K3326X among individuals with familial pancreatic cancer. Oncogene 24: 3652-3656.
49. Akbari MR, Malekzadeh R, Nasrollahzadeh D, Amanian D, Islami F, et al. (2008) Germline BRCA2 mutations and the risk of esophageal squamous cell carcinoma. Oncogene 27: 1290-1296.
50. Cancer Genome Atlas Research N (2013) Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 368: 2059-2074.
51. Kim MS, An CH, Yoo NJ, Lee SH, (2013) Frameshift mutations of chromosome cohesion-related genes SGOL1 and PDS5B in gastric and colorectal cancers with high microsatellite instability. Hum Pathol 44: 2234-2240.
52. Cuadrado A, Remeseiro S, Gomez-Lopez G, Pisano DG, Losada A, (2012) The specific contributions of cohesin-SA1 to cohesion and gene expression: implications for cancer and development. Cell Cycle 11: 2233-2238.
53. Bauerschmidt C, Arrichiello C, Burdak-Rothkamm S, Woodcock M, Hill MA, et al. (2010) Cohesin promotes the repair of ionizing radiation-induced DNA double-strand breaks in replicated chromatin. Nucleic Acids Res 38: 477-487.
54. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, et al. (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825.
55. McLellan JL, O'Neil NJ, Barrett I, Ferree E, van Pel DM, et al. (2012) Synthetic lethality of cohesins with PARPs and replication fork mediators. PLoS Genet 8: e1002574.
56. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, et al. (2012) Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483: 570-575.
57. Drmanac R, Sparks AB, Callow MJ, Halpern AL, Burns NL, et al. (2010) Human genome sequencing using unchained base reads on self-assembling DNA nanoarrays. Science 327: 78-81.
58. Wang K, Li M, Hakonarson H, (2010) ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 38: e164.
59. Krzywinski M, Schein J, Birol I, Connors J, Gascoyne R, et al. (2009) Circos: an information aesthetic for comparative genomics. Genome Res 19: 1639-1645.
60. Kim D, Salzberg SL, (2011) TopHat-Fusion: an algorithm for discovery of novel fusion transcripts. Genome Biol 12: R72.
61. McPherson A, Hormozdiari F, Zayed A, Giuliany R, Ha G, et al. (2011) deFuse: an algorithm for gene fusion discovery in tumor RNA-Seq data. PLoS Comput Biol 7: e1001138.
62. Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, et al. (2010) Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol 28: 511-515.